The virus, G207, is a modified herpes simplex virus that in two previous UAB studies has been shown to be safe when used as a sole therapy. The new findings, published April 8, 2014 in Molecular Therapy, indicate the virus is also safe when used in combination with low doses of radiation therapy.
The study examined nine patients with malignant glioma, and all nine tolerated the therapy well. None developed encephalitis, the brain inflammation often associated with herpes simplex; the gene responsible for causing encephalitis has been removed from G207. Some patients also showed evidence of tumor reduction, and survival rates were increased for others.
âThis was a phase one study designed foremost to see whether the therapy was safe,â said James M. Markert, M.D., Ph.D., professor and chair of the Department of Neurosurgery at UAB and the studyâs first author. âWhile this study, with a limited number of patients and no controls, prevents any conclusions about the efficacy of this treatment, the decrease in tumor size seen on MRIâs in some patients, as well as an increase in survival in some patients without other proven treatment options, is highly encouraging.â
G207 was administered directly to glioma cells in the brain, followed the next day by a low-dose radiation treatment.
|âWhile we cannot draw any firm conclusions from just two study subjects, we are encouraged to note that both of the compassionate-use patients tolerated the second dose extremely well, indicating that the drug may be suitable for multiple use.â
While the study was designed for each patient to receive one dose of G207, two of the nine patients received a second dose as part of a compassionate-use protocol.
âWhile we cannot draw any firm conclusions from just two study subjects, we are encouraged to note that both of the compassionate-use patients tolerated the second dose extremely well, indicating that the drug may be suitable for multiple use,â said Markert.
UAB is gearing up for another study with a new modified version of herpes simplex virus called M032. Preliminary studies have indicated M032 could be an even more effective therapy. It includes a genetically engineered protein called IL12, which the researchers believe will induce a stronger immune response and will contribute to increased anti-angiogenesis, the process of shutting off the blood supply to tumor cells, denying oxygen and essential nutrients.
âThis study showed the safety and the potential for clinical response of single-dose HSV therapy augmented with radiation in the treatment of malignant glioma patients,â said Markert. âAdditional studies with modified viruses such as G207 in the treatment of human glioma are certainly warranted from the results of this trial.â
Gliomas account for about a third of brain tumors, and survival rates are poor; only about half of the 10,000 Americans diagnosed with malignant glioma survive the first year, and only about one-quarter survive for two years.